Drug overdose--a hidden hazard of obesity.
作者信息
Cox J, Penn N, Masood M, Hancock A K, Parker D
机构信息
Oncology Unit, Bradford Royal Infirmary.
出版信息
J R Soc Med. 1987 Nov;80(11):708-9. doi: 10.1177/014107688708001118.
Abstract
摘要
相似文献
1
Drug overdose--a hidden hazard of obesity.药物过量——肥胖的一个潜在危害。
J R Soc Med. 1987 Nov;80(11):708-9. doi: 10.1177/014107688708001118.
2
Brain natriuretic peptide and shortness of breath in the emergency department.急诊科中的脑钠肽与呼吸急促
CMAJ. 2018 Nov 19;190(46):E1361-E1363. doi: 10.1503/cmaj.170770. Epub 2018 Nov 18.
3
[Adriamycin cardiomyopathy].
Med Welt. 1984 Jan 27;35(4):103-8.
4
[Cardiotoxic effect of adriamycin].[阿霉素的心脏毒性作用]
Kardiologiia. 1988 Apr;28(4):110-4.
5
6
Peripartum cardiomyopathy occurring in a patient previously treated with doxorubicin.围产期心肌病发生在一名先前接受过阿霉素治疗的患者身上。
Am J Med Sci. 1997 Dec;314(6):399-400. doi: 10.1097/00000441-199712000-00007.
7
Combination chemotherapy with adriamycin (NSC-123127) in metastatic mammary carcinoma.
Cancer Chemother Rep. 1974 Mar-Apr;58(2):251-3.
8
Development of anthracycline-induced dilated cardiomyopathy due to mutation on LMNA gene in a breast cancer patient: a case report.因 LMNA 基因突变导致乳腺癌患者发生蒽环类药物诱导的扩张型心肌病：病例报告。
BMC Cardiovasc Disord. 2019 Jul 16;19(1):169. doi: 10.1186/s12872-019-1155-7.
9
Transient congenital dilated cardiomyopathy after maternal R-CHOP chemotherapy during pregnancy.孕期母亲接受R-CHOP化疗后出现的短暂性先天性扩张型心肌病。
Reprod Toxicol. 2017 Aug;71:146-149. doi: 10.1016/j.reprotox.2017.05.008. Epub 2017 May 25.
10
Combination chemotherapy of metastatic breast cancer with vincristine adriamycin and prednisolone.长春新碱、阿霉素和强的松龙联合化疗转移性乳腺癌。
Cancer. 1978 Feb;41(2):396-9. doi: 10.1002/1097-0142(197802)41:2<396::aid-cncr2820410203>3.0.co;2-t.
引用本文的文献
1
Adipocytes impair leukemia treatment in mice.脂肪细胞会损害小鼠的白血病治疗效果。
Cancer Res. 2009 Oct 1;69(19):7867-74. doi: 10.1158/0008-5472.CAN-09-0800. Epub 2009 Sep 22.
2
Clinical pharmacokinetics of drugs in obesity. An update.肥胖人群中药物的临床药代动力学。最新进展。
Clin Pharmacokinet. 1993 Aug;25(2):103-14. doi: 10.2165/00003088-199325020-00003.
3
Dosing of thioTEPA for myeloablative therapy.
Cancer Chemother Pharmacol. 1995;37(1-2):155-60.
本文引用的文献
1
Distribution of adriamycin in cancer patients: tissue uptakes, plasma concentration after IV and hepatic IA administration.阿霉素在癌症患者体内的分布：组织摄取、静脉注射及肝动脉注射后的血浆浓度
Cancer. 1980 May 1;45(9):2231-9. doi: 10.1002/1097-0142(19800501)45:9<2231::aid-cncr2820450902>3.0.co;2-3.
2
Acute doxorubicin toxicity. Relationship to pretreatment liver function, response, and pharmacokinetics in patients with acute nonlymphocytic leukemia.急性阿霉素毒性。与急性非淋巴细胞白血病患者预处理肝功能、反应及药代动力学的关系。
Cancer. 1984 Mar 1;53(5):1042-8. doi: 10.1002/1097-0142(19840301)53:5<1042::aid-cncr2820530505>3.0.co;2-b.
3
Adriamycin chemotherapy--efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule.阿霉素化疗——间歇性单次高剂量方案的疗效、安全性及药理学基础
Cancer. 1974 Jan;33(1):19-27. doi: 10.1002/1097-0142(197401)33:1<19::aid-cncr2820330107>3.0.co;2-m.
4
Pharmacokinetics and metabolism of adriamycin in man.阿霉素在人体中的药代动力学与代谢
Clin Pharmacol Ther. 1973 Jul-Aug;14(4):592-600. doi: 10.1002/cpt1973144part1592.
5
Risk factors for doxorubicin-induced congestive heart failure.阿霉素诱导的充血性心力衰竭的危险因素。
Ann Intern Med. 1979 Nov;91(5):710-7. doi: 10.7326/0003-4819-91-5-710.
Zotero 插件